With the advent of PDL1 and PD1 based options such as atezolizumab, nivolumab, durvalumab, and pembrolizumab, and their use in wide variety of cancers, there is the opinion that urogenital cancers may also benefit from these new therapies. Here, CD274 is linked to urogenital neoplasm.